Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9602488 | 0.90 | TSHR (0.58) | PAOXKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL8433585 | 0.85 | ALDH1A1 (0.66) | GAAALDH1A1PAOXLMNAKDM4E | |
| SCHEMBL23699040 | 0.85 | GAA (0.62) | GAAALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL12330918 | 0.85 | GAA (0.67) | GAAALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL2691461 | 0.85 | GAA (0.66) | GAAALDH1A1PAOXLMNAKDM4E | |
| SCHEMBL12434010 | 0.84 | GAA (0.69) | GAAALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL7245255 | 0.83 | ADRA1A (0.57) | GAAALDH1A1MAPK1ADRA1ASMN1; SMN2 | |
| SCHEMBL14393566 | 0.83 | ALDH1A1 (0.64) | GAAALDH1A1PAOXLMNAKDM4E | |
| SCHEMBL18628071 | 0.82 | GAA (0.62) | GAAALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL8252118 | 0.81 | TP53 (0.79) | GAAALDH1A1LMNAKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033436-A1 | DERIVATIVE OF SARSASAPOGENIN, PHARMACEUTICAL COMPOSITION AND USE THEREOF | PHYTOVENT BIOPHARMA (CN) | 2022-02-03 | — | — | US | disclosed |
| US-9943498-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2018-04-17 | — | — | US | disclosed |
| US-9943498-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2018-04-17 | — | — | US | disclosed |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-9394324-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-9394324-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-20130109662-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130109662-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-5037824-A | Cardiotonic, antiischemic agents | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1991-08-06 | — | — | US | disclosed |
| EP-0387070-A2 | N-Containing heterocyclic compounds, processes for the preparation thereof and composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109662-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | FECH, SDHB, SLC40A1 | GAA 215/4885ALDH1A1 1539/4885PAOX 1366/4885 |
| US-20220033436-A1 | DERIVATIVE OF SARSASAPOGENIN, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SARS1, ACE2, FURIN | GAA 228/4885ALDH1A1 2025/4885PAOX 3066/4885 |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | FECH, SDHB, SLC40A1 | GAA 215/4885ALDH1A1 1539/4885PAOX 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.